Shoucheng Buys Back 20M Shares in 2 Days, Signals Strong Bet

HONG KONG, July 31, 2025 – (ACN Newswire) –Shoucheng Holdings Limited (0697. HK) has actually declared its self-confidence in long-lasting principles by carrying out aggressive share buybacks on July 29 and 30, obtaining an overall of 20.65 million shares at an expense of HK$ 37.93 million, with rates varying from HK$ 1.80 to HK$ 1.87 per share.

This becomes part of a wider buyback technique– given that early July, the business has actually bought over 36 million shares, amounting to more than HK$ 66 million in capital released. According to management, these buybacks show not just near-term assessment self-confidence, however likewise long-lasting belief in the business’s tactical instructions in robotics and health care innovation.

“The buyback is not just about stabilizing the share price. It is an expression of long-term commitment to our shareholders and a vote of confidence in the commercial potential of our robotics and healthcare portfolios,” the management mentioned.

Portfolio Companies Advance Toward IPO Milestones

Shoucheng’s capital return technique is matched by strong development throughout its portfolio. 2 of its most prominent investees– IMUNOPHARM and Unitree Robotics– are now formally getting ready for IPOs, indicating a near-term worth awareness window.

IMUNOPHARM, a leader in China’s CAR-T treatment area, signed a listing assistance contract with CITIC Securities on July 23, 2025, formally introducing its STAR Market IPO procedure. Unitree Robotics signed its IPO assistance arrangement previously in July. Established in 2016, Unitree is worldwide acknowledged for its management in quadruped and humanoid robotics, having actually originated the mass commercialization of high-performance legged robotics. Its humanoid robotics, the H1 and G1, are currently in the market and included at significant international occasions consisting of CES and the CCTV Spring Festival Gala. Unitree has actually submitted over 200 patent applications and kept success because 2020, with yearly earnings surpassing RMB 1 billion.

The double IPO development of IMUNOPHARM and Unitree not just confirms Shoucheng’s early-stage financial investment judgment, however likewise indicates that numerous of its frontier-tech bets are approaching money making.

Northeast Securities: Robotics Strategy Backed by Cash Flow, Industrial Scenarios

According to Northeast Securities, Shoucheng Holdings is the leading operator of parking facilities in China, having actually consistently protected high-frequency agreements for significant airport parking concessions, each with yearly throughput in the 10s of millions. The company’s repeating and robust capital from its parking and commercial realty operations supplies the monetary foundation for its tactical growth into robotics financial investment.

As China’s robotics market goes into a crucial commercialization window, Shoucheng’s special dual-engine design–“invest with the left hand, run with the right”– has actually become its 2nd development curve.

In early 2024, Shoucheng and Beijing Guoguan collectively introduced the Beijing Robotics Industry Development Investment Fund, with a preliminary target size of RMB 10 billion. Ever since, the company has actually invested– through several fund platforms– in top-tier robotics business such as Unitree Robotics, DEEP Robotics, Galbot, Volant Aerotech. These business cover humanoid robotics, medical robotics, commercial automation, and more.

What makes Shoucheng’s robotics financial investment technique unique is its integrated commercial circumstance benefit. The business runs over 100 parking centers and handles over 1 million square meters of commercial park area throughout China, using plentiful real-world screening environments. This speeds up item commercialization, feeds functional information back into item models, and makes it possible for co-evolution in between Shoucheng and its portfolio business.

In February 2025, Shoucheng officially developed Beijing Shoucheng Robotics Technology Co., Ltd., additional institutionalising its commercial platform. Moving forward, the conversion of internal situations into real robotics order– consisting of implementations by means of REIT-backed homes and industry-specific usage cases– will continue to verify this integrated method. With its platform now linking capital, use-case, and need, Shoucheng is anticipated to sustain strong exposure in robotics commercialization moving forward.

As both Imunopharm and Unitree Robotics– Shoucheng Holdings’ crucial portfolio business in the fields of medical and robotics innovations– development towards IPO, the business is approaching an important inflection point where tactical financial investment starts to transform into concrete capital returns.

The current share buybacks are not just a direct signal of self-confidence in Shoucheng’s intrinsic worth, however likewise show its exact grasp of the timing for worth awareness.

Versus the background of a polarized assessment landscape in Hong Kong’s equity market, Shoucheng Holdings’ constant buyback effort assists support financier belief while strengthening market expectations. With the upcoming World Robot Conference and Humanoid Robot Games set to shine a spotlight on the sector, the business is poised to take advantage of a merging of commercialization momentum and evaluation healing.

From facilities operator to innovation worth enabler, from tactical organizer to capital return administrator– Shoucheng Holdings’ 2nd development curve is now noticeably unfolding.

Published by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF]

Subject: Press release summary